Approved indications and other possible utilizations of anti-TNFa biologic drugs

Abstract Views: 1081
PDF: 844
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

The article describes the EMEA approved indications of TNFa antagonists (adalimumab, etanercept and infliximab) in the various clinical conditions and their increasing use in diseases other than those already approved. The Authors discuss their use during pregnancy, the efficacy of a second TNFa antagonist after failure or side effects development with a previous biologic agent and the different efficacy of the various agents depending on the different clinical conditions.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Grassi, W., & Montecucco, C. (2005). Approved indications and other possible utilizations of anti-TNFa biologic drugs. Reumatismo, 57(s4), 30–33. https://doi.org/10.4081/reumatismo.2005.4s.30